Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer.

Abdel-Razeq H.

Cancer Manag Res. 2019 May 8;11:4273-4282. doi: 10.2147/CMAR.S204069. eCollection 2019. Review.

2.

Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ.

JAMA Oncol. 2016 Jan;2(1):65-73. doi: 10.1001/jamaoncol.2015.3251. Review.

3.

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.

Shen YW, Zhang XM, Lv M, Chen L, Qin TJ, Wang F, Yang J, Liu PJ, Yang J.

Onco Targets Ther. 2015 Nov 13;8:3349-59. doi: 10.2147/OTT.S95936. eCollection 2015.

4.

Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.

Blumenfeld Z, Zur H, Dann EJ.

Oncologist. 2015 Nov;20(11):1283-9. doi: 10.1634/theoncologist.2015-0223. Epub 2015 Oct 13.

5.

Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.

Blumenfeld Z, Evron A.

Expert Opin Pharmacother. 2015 May;16(7):1009-20. doi: 10.1517/14656566.2015.1031654. Epub 2015 Mar 31. Review.

PMID:
25826240
6.

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.

Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, Del Mastro L.

Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7. Review.

PMID:
26347105
7.

Fertility after breast cancer treatment.

Kasum M, Beketić-Orešković L, Peddi PF, Orešković S, Johnson RH.

Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:13-8. doi: 10.1016/j.ejogrb.2013.11.009. Epub 2013 Nov 17. Review.

PMID:
24315568
8.

Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.

Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C.

Fertil Steril. 2014 Sep;102(3):808-815.e1. doi: 10.1016/j.fertnstert.2014.06.003. Epub 2014 Jul 17. Review.

PMID:
25044080
9.

Utility of GnRH-agonists for Fertility Preservation in Women With Operable Breast Cancer: Is It Protective?

Bedoschi G, Turan V, Oktay K.

Curr Breast Cancer Rep. 2013 Dec 1;5(4):302-308.

10.

Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.

Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, Jiao S.

Breast. 2013 Apr;22(2):150-157. doi: 10.1016/j.breast.2012.12.008. Epub 2013 Jan 5.

11.

Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.

Hickman LC, Valentine LN, Falcone T.

Am J Obstet Gynecol. 2016 Oct;215(4):415-22. doi: 10.1016/j.ajog.2016.06.053. Epub 2016 Jul 13. Review.

PMID:
27422055
12.

Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.

Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L.

Ann Oncol. 2013 Sep;24(9):2224-35. doi: 10.1093/annonc/mdt196. Epub 2013 May 24. Review.

PMID:
23709175
13.

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C.

Clin Med Insights Reprod Health. 2019 Mar 9;13:1179558119828393. doi: 10.1177/1179558119828393. eCollection 2019. Review.

14.

Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.

Senra JC, Roque M, Talim MCT, Reis FM, Tavares RLC.

Ultrasound Obstet Gynecol. 2018 Jan;51(1):77-86. doi: 10.1002/uog.18934. Epub 2017 Dec 1. Review.

15.

Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review.

Cruz MR, Prestes JC, Gimenes DL, Fanelli MF.

Fertil Steril. 2010 Jun;94(1):138-43. doi: 10.1016/j.fertnstert.2009.02.055. Epub 2009 Apr 1. Review.

PMID:
19339000
16.

Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis.

Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC.

Hum Reprod. 2016 Dec;31(12):2737-2749. Epub 2016 Sep 22. Review.

PMID:
27664208
17.

FERTILITY PRESERVATION IN YOUNG WOMEN WITH EARLY-STAGE BREAST CANCER.

Vuković P, Kasum M, Raguž J, Lonjak N, Bilić Knežević S, Orešković I, Beketić Orešković L, Čehić E.

Acta Clin Croat. 2019 Mar;58(1):147-156. doi: 10.20471/acc.2019.58.01.19. Review.

18.

Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.

Lambertini M, Cinquini M, Moschetti I, Peccatori FA, Anserini P, Valenzano Menada M, Tomirotti M, Del Mastro L.

Eur J Cancer. 2017 Jan;71:25-33. doi: 10.1016/j.ejca.2016.10.034. Epub 2016 Dec 9. Review.

PMID:
27940355
19.

Preservation of ovarian function and fertility despite gonadotoxic chemotherapy.

Blumenfeld Z.

Expert Rev Endocrinol Metab. 2012 Sep;7(5):567-576. doi: 10.1586/eem.12.40.

PMID:
30780892

Supplemental Content

Support Center